Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).

Journal of cachexia, sarcopenia and muscle·2026
Same author

Effects of ABCG2 dysfunction on hyperuricemia progression in premenopausal and postmenopausal women.

Human cell·2026
Same author

Rhino-orbito-cerebral fungal infection associated with mixed Cladosporium halotolerans and Penicillium corylophilum, complicated by internal carotid artery occlusion and ischemic stroke: a case report.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2026
Same author

Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion).

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Discovery of gene-alcohol interaction loci influencing blood pressure in 1.1 million individuals from multiple populations.

Research square·2026

Related Experiment Video

Updated: Jul 18, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

[Non-Small Cell Lung Cancer].

Ken Yamamoto1, Akito Hata

  • 1Division of Thoracic Oncology, Kobe Minimally Invasive Cancer Center.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 23, 2023
PubMed
Summary
This summary is machine-generated.

Oligometastases (Oligo-meta) in non-small cell lung cancer (NSCLC) may benefit from combined local therapy and standard treatments. Integrating local therapies with immune checkpoint inhibitors shows promise for enhanced therapeutic effects in NSCLC oligometastatic disease.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.4K

Related Experiment Videos

Last Updated: Jul 18, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.4K

Area of Science:

  • Oncology
  • Cancer Metastasis

Context:

  • Oligometastases (Oligo-meta) are defined by a limited number of metastases amenable to local treatment.
  • Initially defined in breast cancer, the concept is now applied to non-small cell lung cancer (NSCLC).
  • NSCLC can spread to multiple organs, necessitating diverse local treatment strategies for oligometastatic disease.

Purpose:

  • To explore the potential benefits of local therapy in addition to standard treatment for NSCLC oligometastases.
  • To highlight the need for multidisciplinary treatment approaches considering patient factors and metastatic sites.
  • To discuss the emerging role of immune checkpoint inhibitors in combination with local therapies for NSCLC oligometastases.

Summary:

  • Local treatment of oligometastases in NSCLC requires a multidisciplinary approach due to varied metastatic sites.
  • Combining local therapies with standard treatments, including immune checkpoint inhibitors, may improve outcomes.
  • Ongoing clinical trials are investigating the efficacy of combining local therapies with immune checkpoint inhibitors for NSCLC oligometastases.

Impact:

  • Suggests a potential improvement in survival for NSCLC patients with oligometastases.
  • Emphasizes the importance of personalized, collaborative care in managing metastatic lung cancer.
  • Highlights promising new therapeutic strategies involving immunotherapy and targeted local treatments.